An observational study in Decompensated Liver Cirrhosis, Primary Biliary Cholangitis and Primary Sclerosing Cholangitis, sponsored by Assistance Publique - Hôpitaux de Paris. Recruiting at 53 sites in 7 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-07-29.
Sponsored by Assistance Publique - Hôpitaux de Paris · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 25 studies in Liver Cirrhosis, Biliary with a site in Italy — 5 open to participants now, 11 under way, 4 of them phase 3. Liver Cirrhosis, Biliary · Italy.
Among the 25 studies in Liver Cirrhosis, Biliary with a site in Italy, this one is the only one that started in 2025, is one of 5 observational ones, reaches primary completion later than 4 of the 10 other live ones, and was the 21st registered.
214 studies on the registry are indexed under Liver Cirrhosis, Biliary; 48 are open to participants now.
Browse Liver Cirrhosis, Biliary studies →5 of the 25 studies in Liver Cirrhosis, Biliary with a site in Italy are open now. Recruiting first, the newest first:
Assistance Publique - Hôpitaux de Paris · Sites in Italy, Belgium, France and 2 more countries
Ages 18–70
Gilead Sciences · Sites in Italy, United States, Argentina and 26 more countries
Ages 18+
Ipsen · Sites in Italy, United States, Argentina and 25 more countries
Ages 18+
University of Milano Bicocca · Sites in Italy
Ages 18+
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 34 Liver Cirrhosis, Biliary studies recruiting now, 16 (47%) set no upper age limit and 11 (32%) stop at 75 or younger; 3 take children under 18; 4 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
25 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 7 · Phase 3 10 · Phase 4 2
First in 2012; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,500 is above the median of 380 across 54 observational studies indexed under Liver Cirrhosis, Biliary.
Median enrollment 207 across the 19 interventional studies, 630 across the 5 observational. Of the 14 that completed or were terminated, 10 (71%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 25 have an industry lead sponsor. The 10 most frequent:
Assistance Publique - Hôpitaux de Paris is the lead sponsor of 3,598 studies on the registry; 1,038 are open to participants now.
Assistance Publique - Hôpitaux de Paris has 3 studies filed under Liver Cirrhosis, Biliary — fewer than ten, so there is no comparison to draw.
3 of the studies in Liver Cirrhosis, Biliary with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07573514Fondazione Policlinico Universitario Agostino Gemelli IRCCSPatients With Primary Biliary Cholangitis | 2026-12 |
| NCT05050136Mirum Pharmaceuticals, Inc.A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis | 2027-01 |
| NCT07629128Fondazione Policlinico Universitario Agostino Gemelli IRCCSPatients With Primary Biliary Cholangitis(PBC) | 2027-05 |
Add all 3 to your calendar (.ics) → With an account.
Among the 25 studies in Liver Cirrhosis, Biliary with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Intro:
The present clinical research protocol is part of the LEOPARD European project (Grant n° 101080964 Horizon Europe) which aims to design and validate new predictive models of mortality among liver transplantation (LT) candidates. MELD based-liver graft allocation systems have become increasingly inaccurate over the last decade to predict mortality/dropout of liver transplantation (LT) candidates on the waitlist (WL). Wide disparities in mortality/dropout on the WL also exist across European countries, ranging from 5 to 30% according to transplantation indications and countries. In this setting, the European Commission- Horizon Europe funded-LEOPARD project intends to design new, 2nd generation, AI-machine learning-based predictive models of delisting in LT candidates, to better serve on time patients with the highest risk of dropout on the WL and to improve equity of access to LT across Europe.
Hypothesis/Objective:
The scientific justification of the LEOPARD TVDCS is therefore to collect a large set of data in liver transplantation candidates listed in Europe a) to design and b) to validate LEOPARD 2nd generation AI-based predictive models of mortality/dropout The primary objective is to develop new predictive models of mortality/drop out on the waitlist in patients with decompensated cirrhosis, or other end-stage chronic liver diseases, and in patients listed for Hepato-cellular carcinoma (HCC).
Method:
Longitudinal multicenter prospective health care data collection cohort study in 2 sets : Training/development set : Prospective health care data collection in 3,000 patients listed in 50 centres across 7 countries and Validation set: Prospective health care data collection in 1,500 subsequent patients listed in the same 50 centres.
Adults patients listed for :
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Adult [age 18;70] patients listed for:
(*Of note, enrolment of patients with T1 tumors (1 single tumor \< 2 cm diameter) not amenable to loco-regional therapies because of decompensation, and prioritized under the MELD system, will be allowed in Subset 1.)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Decompensated cirrhosis as primary diagnosis, irrespective of liver disease etiology
Other chronic end-stage liver diseases requiring LT, to be listed under a MELD-based allocation system (examples: primary biliary cholangitis, primary sclerosing cholangitis etc…)
Hepato-cellular carcinoma as primary diagnosis, whatever the etiology of the underlying liver disease with or without underlying cirrhosis
Clinical primary endpoint considered as the event of interest to be predicted will be a composite of number of participants with mortality or drop out for being too sick on transplantation waiting list.
* 3-month mortality/dropout for being too sick after listing in subsets 1 and 2 * 12-month mortality/dropout for being too sick (tumor progression) after listing in subset 3
Time frame: 3 months after listing in subsets 1 & 2 ; 12 months after listing in subset3
Number of participants with 6- and 9-month pre LT mortality dropout for being too sick (all subsets)
Mortality (all subsets)
Time frame: 6 and 9 months after listing
Causes of death/drop-out for being too sick
Causes of death/drop-out (all subsets)
Time frame: From date of inclusion until date of death from any cause or date of drop-out for being too sick, whichever came first, assessed up to 12 months
Incidence of delisting for patient's decision or clinical improvement
delisting for patient's decision or clinical improvement
Time frame: From date of inclusion until date of delisting for patient's decision or clinical improvement, assessed up to 12 months
Time from listing to death/dropout
Duration from listing to death/dropout (days)
Time frame: From date of listing until date of death from any cause or date of drop-out for being too sick, whichever came first, assessed up to 12 months
Time to transplantation
Duration from listing to transplantation (days)
Time frame: From date of listing until date of transplantation, assessed up to 12 months
Number of participants with 6-month and 12 month post LT survival in subsets 1 to 3
Survival in Training cohort subsets 1 to 3
Time frame: 6 months and 12 months after liver transplantation
Number of participants with 12-month HCC recurrence in subset 3
HCC recurrence in Training cohort subset 3
Time frame: 12 months after liver transplantation
Number of participants with 6-month post-LT survival (all subsets)
Survival in Validation cohort all subsets
Time frame: 6 month after liver transplantation
6-month transplant benefit (all subsets)
Relevant comorbidities (diabetes, hypertension, stroke, coronary disease, cancers, alcohol and tobacco consumption) in Validation cohort all subsets
Time frame: 6 months after liver transplantation
Plan to share: No — IPD will not be shared. Datas are own by Assistance Publique-Hôpitaux de Paris (AP-HP), please contact sponsor for further information.
No publications or documents are linked to this record.
Started Feb 2025 (actual). Primary completion is estimated for Mar 2028, 37 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique - Hôpitaux de Paris →